Journal Mobile Options
Table of Contents
Vol. 213, No. 2, 2006
Issue release date: August 2006
Dermatology 2006;213:150–152
(DOI:10.1159/000093856)

Scleromyxedema, a Positive Effect with Thalidomide

Jacob S.E. · Fien S. · Kerdel F.A.
aDepartment of Dermatology and Cutaneous Surgery and Florida University of Miami, and bFlorida Academic Dermatology Centers, Miami, Fla., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Scleromyxedema is a rare dermatological disorder marked by widespread symmetric 2- to 3-mm, firm, waxy, closely spaced papules involving the hands, forearms, face, neck, upper trunk and thighs. The most common extracutaneous manifestation of scleromyxedema is a benign plasma cell dyscrasia. Treatment of scleromyxedema is limited by the lack of long-term results, toxicity and significant adverse side effects. We report a severe case of scleromyxedema who had marked improvement when treated with thalidomide.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rongioletti F, Rebora A: Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001;44:273–281.
  2. Dinneen AM, Dicken CH: Scleromyxedema. J Am Acad Dermatol 1995;33:37–43.
  3. Jackson EM, English JC 3rd: Diffuse cutaneous mucinoses. Dermatol Clin 2002;20:493–501.
  4. Harper RA, Rispler J: Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978;199:545–547.
  5. Yaron M, Yaron I, Yust I, Brenner S: Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 1985;12:171–175.
  6. Chanda JJ: Scleromyxedema. Cutis 1979;24:549–552.
  7. Bonnetblanc JM, Bedane C: Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up. Arch Dermatol 1991;127:1733–1734.
  8. Horn KB, Horn MA, Swan J, Singhal S, Guitart J: A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol 2004;51(2 suppl):S120–S123.

    External Resources

  9. Rayson D, Lust JA, Duncan A, Su WP: Scleromyxedema: a complete response to prednisone. Mayo Clin Proc 1999;74:481–484.
  10. Farr PM, Ive FA: PUVA treatment of scleromyxedema. Br J Dermatol 1984;110:347–350.
  11. Lowe NJ, Dufton PA, Hunter RD, Vickers CF: Electron-beam treatment of scleromyxedema. Dermatology 1982;106:449–453.
  12. Milam CP, Cohen LE, Fenske NA, Ling NS: Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 1988;19:469–477.
  13. Hisler BM, Savoy LB, Hasimoto K: Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 1991;24:854–857.
  14. Keong CH, Asaka Y, Fukuro S, Miyamoto C, Katsumata M, Iino Y, Komiya T: Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol 1990;22:842–844.
  15. Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M, Rustin MH: Scleromyxedema: response to high-dose intravenous immunoglobulin. J Am Acad Dermatol 2000;43:403–408.
  16. Berkson M, Lazarus GS, Uberti-Benz M, Rock AH: Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol 1991;25:724.
  17. Kaufman D, Truhan AP, Roenigk HH Jr: Scleromyxedema: systemic manifestations and cosmetic improvement from dermabrasion. Cutis 1987;39:321–324.
  18. Feldman P, Shapiro L, Pick AI, Slatkin MH: Scleromyxedema: a dramatic response to melphalan. Arch Dermatol 1969;99:51–56.
  19. Harris RB, Perry HO, Kyle RA, Winkelmann RK: Treatment of scleromyxedema with melphalan. Arch Dermatol 1979;115:295–299.
  20. Bata-Csorgo Z, Husz S, Foldes M, Korom I, Molnar K, Morvay M, Dobozy A: Scleromyxedema. J Am Acad Dermatol 1999;41:343–346.
  21. Saigoh S, Tashiro A, Fujita S, Matsui M, Shibata S, Takeshita H, Duan H, Moroi Y, Urabe K, Koga T, Furue M: Successful treatment of intractable scleromyxedema with cyclosporine A. Dermatology 2003;207:410–411.
  22. Davis LS, Sanal S, Sangueza OP: Treatment of scleromyxedema with 2-chlorodeoxyadenosine. J Am Acad Dermatol 1996;35:288–290.
  23. Howsden SM, Herndon JH Jr, Freeman RG: Lichen myxedema: a dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol 1975;111:1325–1330.
  24. Jessen RT, Straight M, Becker LE: Lichen myxedematosus: treatment with cyclophosphamide. Int J Dermatol 1978;17:833–839.
  25. Verity MA, Toop J, McAdam LP, et al: Scleromyxedema myopathy: histochemical and electron microscopic observations. Am J Clin Pathol 1978;69:446–451.
  26. McAdam LP, Pearson CM, Pitts WH, et al: Papular mucinosis with myopathy, arthritis, and eosinophilia: a histopathologic study. Arthritis Rheum 1977;20:989–996.
  27. Wieder JM, Barton KL, Baron JM, Soltani K: Lichen myxedematosus treated with chlorambucil. Dermatol Surg Oncol 1993;19:475–476.
  28. Tschen JA, Chang JR: Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 1999;40:303–307.
  29. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–1571.
  30. Stirling DI: Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1988;17:231–242.

    External Resources

  31. Tseng S, Pak G, Washenik K, et al: Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969–979.
  32. Radomsky CL, Levine N: Thalidomide. Dermatol Clin 2001;19:87–103.
  33. Calabrese L, Fleischer AB: Thalidomide: current and potential clinical applications. Am J Med 2000;108:487–495.
  34. Sander CS, Kaatz M, Elsner P: Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide. Dermatology 2004;208:149–152.
  35. Kolivras A, De Maubeuge J, Andre J, Song M: Thalidomide in refractory vulvar ulcerations associated with Crohn’s disease. Dermatology 2003;206:381–383.
  36. Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M: Neurological toxicity of long-term (>1 years) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74:212–216.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00